thalidomide has been researched along with Encephalopathy, Toxic in 12 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is remarkably active in advanced relapsed and refractory multiple myeloma (MM), so that its use has been recently proposed either in newly diagnosed patients or as maintenance treatment after conventional or high-dose therapy." | 9.11 | Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. ( Baccarani, M; Cangini, D; Cavo, M; Cellini, C; Pastorelli, F; Perrone, G; Plasmati, R; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E, 2005) |
| "We analyzed DNA from 1,495 patients with multiple myeloma." | 5.37 | Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. ( Child, JA; Corthals, SL; Davies, FE; Dickens, NJ; Durie, BG; Goldschmidt, H; Gregory, WM; Johnson, DC; Lokhorst, HM; Morgan, GJ; Ross, FM; Sonneveld, P; Van Ness, B; Walker, BA, 2011) |
| "Thalidomide is remarkably active in advanced relapsed and refractory multiple myeloma (MM), so that its use has been recently proposed either in newly diagnosed patients or as maintenance treatment after conventional or high-dose therapy." | 5.11 | Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. ( Baccarani, M; Cangini, D; Cavo, M; Cellini, C; Pastorelli, F; Perrone, G; Plasmati, R; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E, 2005) |
| "2 years) underwent clinical and neurophysiologic assessment at baseline and at 2 (8 patients, group A) or 5 years (11 patients, group B) after starting lenalidomide therapy for relapsed/refractory multiple myeloma." | 3.83 | Lenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study. ( Barilà, G; Berno, T; Briani, C; Cacciavillani, M; Campagnolo, M; Dalla Torre, C; De March, E; Ermani, M; Lico, A; Lucchetta, M; Salvalaggio, A; Zambello, R, 2016) |
| "Thalidomide was used for graft-vs-host disease, pyoderma gangrenosum, and discoid lupus with dosages ranging from 100 to 1,200 mg/day for 5 to 16 months (cumulative dosages of 24 to 384 g)." | 2.70 | Thalidomide-induced neuropathy. ( Chaudhry, V; Cornblath, DR; Corse, A; Freimer, M; Simmons-O'Brien, E; Vogelsang, G, 2002) |
| " However, soon after their introduction into clinical practice, chemotherapy-induced peripheral neurotoxicity (CIPN) emerged as their main non-hematological and among dose-limiting adverse events." | 2.61 | Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment. ( Alberti, P; Argyriou, AA; Islam, B; Kolb, N; Lustberg, M; Staff, NP, 2019) |
| " Depending on dosage and agent used symptoms resolve completely or not." | 2.42 | [Neurotoxic effects of medications: an update]. ( Arné-Bès, MC, 2004) |
| "We analyzed DNA from 1,495 patients with multiple myeloma." | 1.37 | Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. ( Child, JA; Corthals, SL; Davies, FE; Dickens, NJ; Durie, BG; Goldschmidt, H; Gregory, WM; Johnson, DC; Lokhorst, HM; Morgan, GJ; Ross, FM; Sonneveld, P; Van Ness, B; Walker, BA, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Islam, B | 1 |
| Lustberg, M | 1 |
| Staff, NP | 1 |
| Kolb, N | 1 |
| Alberti, P | 1 |
| Argyriou, AA | 1 |
| Mahony, C | 1 |
| McMenemy, S | 1 |
| Rafipay, AJ | 1 |
| Beedie, SL | 1 |
| Fraga, LR | 1 |
| Gütschow, M | 1 |
| Figg, WD | 1 |
| Erskine, L | 1 |
| Vargesson, N | 1 |
| Dalla Torre, C | 1 |
| Zambello, R | 1 |
| Cacciavillani, M | 1 |
| Campagnolo, M | 1 |
| Berno, T | 1 |
| Salvalaggio, A | 1 |
| De March, E | 1 |
| Barilà, G | 1 |
| Lico, A | 1 |
| Lucchetta, M | 1 |
| Ermani, M | 2 |
| Briani, C | 3 |
| Johnson, DC | 1 |
| Corthals, SL | 1 |
| Walker, BA | 1 |
| Ross, FM | 1 |
| Gregory, WM | 1 |
| Dickens, NJ | 1 |
| Lokhorst, HM | 1 |
| Goldschmidt, H | 1 |
| Davies, FE | 1 |
| Durie, BG | 1 |
| Van Ness, B | 1 |
| Child, JA | 1 |
| Sonneveld, P | 1 |
| Morgan, GJ | 1 |
| Chaudhry, V | 2 |
| Cornblath, DR | 1 |
| Corse, A | 1 |
| Freimer, M | 1 |
| Simmons-O'Brien, E | 1 |
| Vogelsang, G | 1 |
| Apfel, SC | 1 |
| Zochodne, DW | 1 |
| Zara, G | 2 |
| Rondinone, R | 1 |
| Della Libera, S | 1 |
| Ruggero, S | 1 |
| Ghirardello, A | 1 |
| Zampieri, S | 1 |
| Doria, A | 1 |
| Cavaletti, G | 1 |
| Beronio, A | 1 |
| Reni, L | 1 |
| Ghiglione, E | 1 |
| Schenone, A | 1 |
| Cocito, D | 1 |
| Isoardo, G | 1 |
| Ciaramitaro, P | 1 |
| Plasmati, R | 2 |
| Pastorelli, F | 2 |
| Frigo, M | 1 |
| Piatti, M | 1 |
| Carpo, M | 1 |
| Arné-Bès, MC | 1 |
| Tosi, P | 1 |
| Zamagni, E | 1 |
| Cellini, C | 1 |
| Cangini, D | 1 |
| Tacchetti, P | 1 |
| Perrone, G | 1 |
| Tura, S | 1 |
| Baccarani, M | 1 |
| Cavo, M | 1 |
| Umapathi, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer[NCT02864030] | Phase 4 | 200 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| Phase I / II Study Of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma[NCT01658904] | Phase 1/Phase 2 | 3 participants (Actual) | Interventional | 2012-07-31 | Terminated (stopped due to study closed prematurely because investigator left National Institutes of Health) | ||
| Rapamycin-Resistant T Cell Therapy of Multiple Myeloma: Relapse Prevention and Relapse Therapy[NCT01239368] | Phase 1/Phase 2 | 34 participants (Actual) | Interventional | 2010-11-10 | Terminated (stopped due to Terminated due to insufficient accrual.) | ||
| Mobilization and Collection of Autologous Stem Cell for Transplantation (ASCT) for Plasma Cell Myeloma (PCM)[NCT01547806] | Phase 2 | 49 participants (Actual) | Interventional | 2012-02-22 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
Engraftment failure is defined as the failure to achieve neutrophil engraftment by day 21; defined from day 0, day of autologous hematopoietic cell transplantation (AHCT), as the first of three consecutive days on which the patient's absolute neutrophil count is greater than 0.5x10(9)/l following the nadir. Transplant related mortality is defined as any subject who dies in the first 100 days post-AHCT of any non-relapse related cause. (NCT01658904)
Timeframe: up to day 100
| Intervention | participants (Number) |
|---|---|
| Cohort 1- CFZ 20 mg/m^2 (Day 1,2) | 0 |
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT01658904)
Timeframe: 8 months and 15 days
| Intervention | participants (Number) |
|---|---|
| Cohort 1- CFZ 20 mg/m^2 (Day 1,2) | 1 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01239368)
Timeframe: Date treatment consent signed to last date off study, 81 months and 6 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 - 1x10(5) T Cells/kg | 1 |
| Cohort 2 - 5x10(5) T Cells/kg | 1 |
| Cohort 3 - 1x10(6) T Cells/kg | 1 |
| Cohort 4 - 3x10(6) T Cells/kg | 2 |
| Cohort 5 - 5x10(6) T Cells/kg | 5 |
| Cohort 5B - 5x10(6) T Cells/kg | 2 |
| Cohort 6 - 15x10(6) T Cells/kg | 3 |
| Cohort 7 - 45x10(6) T Cells/kg | 0 |
| Cohort A - Th1/Tc1.Rapa Prevention of Relapse | 1 |
| Cohort B - Th1/Tc1.Rapa for Relapsed Multiple Myeloma | 4 |
Progressive disease is assessed by the Consensus of the International Myeloma Working Group criteria and is defined as one or more of the following: Increases of greater or equal to 25% in serum M-component (minimum absolute increase of 0.5 g/dl) or urine M-component (minimum absolute increase of 200mg/24h) or percentage of bone marrow plasma cells (minimum absolute percentage of 10%) or size of bone lesions or new plasmacytoma, or development of hypercalcemia solely attributable to the disease. (NCT01239368)
Timeframe: Study completion at 22 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A - Th1/Tc1.Rapa Prevention of Relapse | 1 |
Patients whose tumors shrunk and were disease free after therapy in cohort B. Partial response and complete response were assessed by the Consensus of the International Myeloma Working Group criteria. Partial response is defined as 50% or greater reduction in serum M-protein and 90% or greater reduction in 24-h urinary M-protein (or to less than 200 mg per 24h), 50% or greater reduction in the size of soft tissue plasmacytomas, if present at baseline, no evidence of progressive or new bone lesions if radiographic studies were performed (X-rays not required in absence of clinical indication). Complete response is defined as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and 5% or less plasma cells in bone marrow and no evidence of progressive or new bone lesion if radiographic studies were performed. Progressive disease is increases of ≥25% in serum M-component/urine M-component, or size of bone lesions. (NCT01239368)
Timeframe: Study completion at 22 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort B - Th1/Tc1.Rapa for Relapsed Multiple Myeloma | 2 |
Participants were assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0) (NCT01239368)
Timeframe: 2 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 - 1x10(5) T Cells/kg | 0 |
| Cohort 2 - 5x10(5) T Cells/kg | 0 |
| Cohort 3 - 1x10(6) T Cells/kg | 0 |
| Cohort 4 - 3x10(6) T Cells/kg | 0 |
| Cohort 5 - 5x10(6) T Cells/kg | 0 |
| Cohort 5B - - 5x10(6) T Cells/kg | 0 |
| Cohort 6 - 15x10(6) T Cells/kg | 0 |
| Cohort 7- 45x10(6) T Cells/kg | 0 |
| Cohort A - Th1/Tc1.Rapa Prevention of Relapse | 0 |
| Cohort B - Th1/Tc1.Rapa Prevention of Relapse | 0 |
Progenitor cells by apheresis was determined by flow cytometry. (NCT01547806)
Timeframe: Through Day 2 of collection
| Intervention | Number of CD34 cells per kg/BW (x 10EE6) (Mean) |
|---|---|
| Hematopoietic Progenitor Cells | 6.4 |
Progenitor cells by apheresis was determined by flow cytometry. (NCT01547806)
Timeframe: Through Day 2 of collection
| Intervention | Number of CD34 cells per kg/BW (x 10EE6) (Median) |
|---|---|
| Hematopoietic Progenitor Cells | 6.3 |
The cryopreserved stem cells are stored under Good Manufacturing Practice (GMP) conditions in the National Institutes of Health (NIH) Department of Transfusion Medicine until a referring physician requests the products for standard clinical care. (NCT01547806)
Timeframe: Indefinitely until a referring physician requests the product for standard clinical care or until product(s) is no longer needed and disposed of
| Intervention | products (Number) |
|---|---|
| Hematopoietic Progenitor Cells (HPC) | 49 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01547806)
Timeframe: 27 months and 27 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Hematopoietic Progenitor Cells (HPC) | 16 |
Progenitor cells by apheresis was determined by flow cytometry. The stated goal was a minimum dose of 2x10EE^6/kg following apheresis. (NCT01547806)
Timeframe: Day 1 of apheresis
| Intervention | percentage of patients (Number) |
|---|---|
| Hematopoietic Progenitor Cells (HPC) | 98 |
Progenitor cells by apheresis was determined by flow cytometry. (NCT01547806)
Timeframe: Through Day 2 of collection
| Intervention | percentage of patients (Number) |
|---|---|
| Hematopoietic Progenitor Cells | 2 |
Percentage of patents achieving collecting the minimum but not optimal CD34 cell number. (NCT01547806)
Timeframe: Day one of collection
| Intervention | percentage of patients (Number) |
|---|---|
| Hematopoietic Progenitor Cells | 31 |
Progenitor cells by apheresis was determined by flow cytometry. (NCT01547806)
Timeframe: Through Day 2 of collection
| Intervention | Number of CD34 cells per kg/BW (x 10EE6) (Median) |
|---|---|
| Hematopoietic Progenitor Cells | 6.3 |
Progenitor cells by apheresis was determined by flow cytometry. (NCT01547806)
Timeframe: Through Day 2 of collection
| Intervention | Number of CD34 cells per kg/BW (x 10EE6) (Number) | |
|---|---|---|
| 25th percentile | 75th percentile | |
| Hematopoietic Progenitor Cells | 4.0 | 8.0 |
Here is the percentage of patients that achieved or did not achieve 5 x 10^6 CD34 cells/kg in a single apheresis. (NCT01547806)
Timeframe: Through Day 2 of collection
| Intervention | percentage of patients (Number) | |
|---|---|---|
| Achieved 5 x 10EE CD34 cells/kg | Did not achieve 5 x 10EE CD34 cells/kg | |
| Hematopoietic Progenitor Cells | 65 | 35 |
Percentage of patients that required Plerixafor injection in addition to G-CSF mobilization or none at all (NCT01547806)
Timeframe: One week of mobilization therapy
| Intervention | percentage of patients (Number) | |
|---|---|---|
| Plerixafor + G-CSF | Only G-CSF (no plerixafor) | |
| Hematopoietic Progenitor Cells | 47 | 53 |
3 reviews available for thalidomide and Encephalopathy, Toxic
| Article | Year |
|---|---|
Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment.
Topics: Antineoplastic Agents; Cohort Studies; Furans; Humans; Immunosuppressive Agents; Ketones; Neoplasms; | 2019 |
[Neurotoxic effects of medications: an update].
Topics: Anti-Retroviral Agents; Antineoplastic Agents; Carboplatin; Cisplatin; Colchicine; Docetaxel; Humans | 2004 |
Toxic neuropathy.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Epothilones; Genetic Therapy; Humans; | 2005 |
2 trials available for thalidomide and Encephalopathy, Toxic
| Article | Year |
|---|---|
Thalidomide-induced neuropathy.
Topics: Adult; Bone Marrow Transplantation; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; | 2002 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2005 |
7 other studies available for thalidomide and Encephalopathy, Toxic
| Article | Year |
|---|---|
CPS49-induced neurotoxicity does not cause limb patterning anomalies in developing chicken embryos.
Topics: Angiogenesis Inhibitors; Animals; Body Patterning; Bungarotoxins; Chick Embryo; Embryonic Developmen | 2018 |
Lenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Drug Resi | 2016 |
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Gene | 2011 |
Thalidomide and lenalidomide: overview of the French pharmacovigilance database.
Topics: Databases, Factual; France; Hematologic Diseases; Humans; Immunosuppressive Agents; Lenalidomide; Mu | 2012 |
Thalidomide neuropathy: too much or too long?
Topics: Humans; Immunosuppressive Agents; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Thali | 2004 |
Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus.
Topics: Adult; Electrophysiology; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Middle A | 2004 |
Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neurotoxicity Synd | 2004 |